Zydus Life Science logo

Zydus Life Science

ZYDUSLIFE NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
1.1L Cr
Volatility
Moderate
P/E Ratio
25.49
EBITDA
₹8,985 Cr
Return on Equity
16.99%
Debt to Equity
0.46
Book Value
₹271.78
EPS
₹41.43
52W High
₹1,232.1
52W Low
₹835.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Growth Rate

Revenue Growth
17.64% higher than 3Y
Net Income Growth
8.92% lower than 3Y
Cash Flow Change
-68.79% lower than 3Y
ROE
-2.97% lower than 3Y
ROCE
-12.51% lower than 3Y
EBITDA Margin (Avg.)
4.2% lower than 3Y

AI Analysis — Bull vs Bear

6d ago
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences has a market capitalisation of about Rs 1,19,943 Cr and trades at a P/E of 25.6x and a P/B of 4.34x. Its ROE has held at around 21% over 3, 5 and 10 years. Sales have compounded at 16% over 3 years and 21% on a TTM basis, but TTM profit growth has slowed to 5% from a 3-year profit CAGR of 32%.

Bull Case 7
  • Return on equity has been steady at about 21% over the last year, 3 years and 5 years, and 20% over 10 years. That points to a durable level of capital efficiency across business cycles.
  • Profit has compounded at 32% over 3 years and 19% (18.8%) over 5 years, well ahead of the 10-year profit CAGR of 11%. Earnings growth has picked up in recent years.
  • TTM sales growth of 21% is faster than the 3-year sales CAGR of 16%, the 5-year CAGR of 12% and the 10-year CAGR of 11%. Top-line momentum is currently speeding up.
  • Over 5 years, profit CAGR of 19% has beaten sales CAGR of 12%. This suggests operating leverage and margin gains over the medium term.
  • The stock has returned a 25% CAGR over 3 years and 16% over 1 year, which shows sustained market recognition of the earnings improvement.
  • Over 5 years, the stock CAGR of 16% has lagged the profit CAGR of 19%. Much of the earnings growth has come without a matching expansion in the valuation multiple.
  • A P/B of 4.34x with a 21% ROE works out to an implied earnings yield on book of roughly 4.8%. Given the consistency of returns, that premium to book is moderate rather than extreme.
Bear Case 7
  • TTM profit growth of 5% is far below TTM sales growth of 21% and the 3-year profit CAGR of 32%. This points to margin compression or normalisation from a high base.
  • The 3-year profit CAGR of 32% is about double the 3-year sales CAGR of 16%. Growth this far ahead of revenue may reflect one-off or product-specific gains, such as high-margin US generic launches, that may not be repeatable.
  • At a P/E of 25.6x against TTM profit growth of 5%, the implied PEG ratio is about 5x on current growth. The valuation leans on earnings growth picking up again.
  • The dividend yield is only 0.08%, so shareholder returns depend almost entirely on share price appreciation rather than income.
  • Over 10 years the stock has compounded at just 12%, roughly in line with 10-year sales CAGR of 11% and profit CAGR of 11%. Long-term returns have been modest compared with the recent 3-year run.
  • The P/B of 4.34x implies a book value of roughly Rs 27,600 Cr against a market cap of about Rs 1,19,943 Cr. The price already builds in sustained 20%+ returns on equity.
  • Debt-to-equity, ROCE and EPS are not available in the dataset, and the 52-week high/low values are reported as 0. That limits any assessment of leverage, capital efficiency beyond ROE, and where the price sits in its recent range.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Headwinds 3
  • Q1 profit falls 35.9% YoY Sep 26

    June-quarter net profit fell 35.9% year-on-year to ₹939.8 crore, even though revenue grew.

  • EBITDA margin down 770 bps Sep 26

    EBITDA fell 7.6% to ₹1,929.4 crore, and the margin contracted to 24.1% from 31.8% a year earlier.

  • North America sales dip YoY Sep 26

    North American formulations sales declined 2.6% year-on-year to ₹3,098 crore. They still rose 4.9% sequentially on volume growth and new launches.

Positives 4
  • Stock hits 52-week high Sep 26

    Shares hit a 52-week high of ₹1,228.25, up 2% intraday, while the BSE Sensex fell 1.4%. Volume nearly doubled to 2.06 million shares, and the stock is up 47% from its Mar 2, 2026 low of ₹835.85.

  • Nil observations at NJ inspection Sep 26

    A USFDA inspection of the pharmacovigilance and post-marketing surveillance system at the New Jersey office ran Sep 22-25, 2026 and ended with nil observations.

  • Q1 revenue up 22% Sep 26

    June-quarter revenue rose 22% YoY to ₹8,017 crore. India branded formulations kept outpacing the market, and international and consumer wellness businesses kept growing.

  • Ascorbic Acid Injection approval, CGT Sep 26

    Final USFDA approval in August covers a generic of Ascor in 25,000 mg/50 mL and 5,000 mg/10 mL strengths, targeting a market of about $11.6 million in annual US sales. Its Competitive Generic Therapy (CGT) status makes it eligible for 180-day exclusivity.

Neutral 2
  • SEZ II inspection: one observation Sep 28

    A USFDA cGMP inspection at the Ahmedabad SEZ II plant ran Sep 21-28, 2026 and ended with one observation and no data integrity issues. The company says it will address the observation quickly.

  • J.P. Morgan India Conference participation Sep 11

    Zydus told stock exchanges it would take part in the J.P. Morgan India Conference 2026 on Sep 21, 2026.

TL;DR: Zydus has strong regulatory momentum: nil observations at its New Jersey inspection, only one non-data-integrity observation at SEZ II, and a CGT-designated injectable approval. These helped push the stock to a 52-week high, about 7% below its ₹1,323.90 record. The main risks are earnings quality, with Q1 profit down 35.9% and the EBITDA margin down to 24.1% from 31.8%, plus a year-on-year decline in North American sales. The trend looks better on regulatory and sequential US growth, and the next test is whether upcoming quarters bring margins back to justify the rally.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
8,017
Expenses
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
6,088
Operating Profit
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
1,929
OPM %
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
24%
Other Income
21
53
60
160
63
68
57
-139
155
75
26
-263
88
Interest
18
9
20
35
32
25
32
77
85
101
130
123
156
Depreciation
180
184
195
205
215
234
229
238
238
302
360
508
555
PBT
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
1,307
Tax %
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
27%
Net Profit
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
990
EPS in Rs
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
9.42
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
28,592
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
20,276
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
8,316
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
29%
Other Income
45
112
127
111
183
-264
-171
2,581
-422
293
50
-7
-74
Interest
68
53
45
91
194
342
164
127
130
81
166
439
510
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
1,725
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
6,007
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
—
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
4,593
EPS in Rs
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
44.94
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
11,065
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
24,106
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
3,698
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,781
2,117
Investing
-465
-860
-2,872
-974
-3,977
-1,012
-835
1,137
1,178
-1,492
-8,363
-7,895
Financing
-351
-935
2,316
52
1,885
-1,094
-2,549
-868
-4,400
-1,810
1,995
5,807
Net Cash Flow
178
99
756
-3
-811
399
-90
2,373
-534
-75
414
28
Free Cash Flow
498
936
-1,623
-116
236
1,617
2,446
1,050
1,697
2,345
5,139
-530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
64
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
160
212
Working Capital Days
6
-1
-34
17
10
-19
-6
19
70
88
3
-40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Life Science insights

71 extracted metrics + investor summaries across FY05–FY27.

Log in — free

Shareholding Pattern

Others1.38%Promot.75.01%Public5.45%FIIs6.88%DIIs11.27%As ofJun 2026

Documents

Frequently Asked Questions about Zydus Life Science

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise...
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd trades as ZYDUSLIFE on the NSE and under code 532321 on the BSE.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of ₹1,13,995 Cr, which places it in the Large Cap band.
What is the PE ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd trades at a PE ratio of 25.49, on earnings per share of ₹41.43, against a book value of ₹271.78 per share.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the last 52 weeks Zydus Lifesciences Ltd has traded between ₹835.5 and ₹1,232.1.
Does Zydus Lifesciences Ltd pay dividends?
Zydus Lifesciences Ltd has a dividend yield of 0.09%.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd reported a return on equity of 16.99%. Its debt-to-equity ratio is 0.46.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 2000-04-18
Face Value ₹ 1
Issued Size 1,00,62,33,990

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSLIFE.md for Zydus Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List